Matthew C. Tattersall
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Matthew C. Tattersall has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
- James H. Stein
University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
8 shared publications - Claudia E. Korcarz
Cardiovascular Research Center, Division of Cardiovascular Medicine, Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, USA
6 shared publications Nizar N. Jarjour
Division of Allergy, Pulmonary and Critical Care Medicine
6 shared publications- Carol C. Mitchell
University of Wisconsin School of Medicine and Public Health, Madison, USA
3 shared publications Kristin M. Hansen
Department of Medicine, Division of Cardiovascular Medicine University of Wisconsin School of Medicine and Public Health Madison WI
3 shared publications- Mats W. Johansson
Division of Allergy, Pulmonary and Critical Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health , 600 Highland Avenue, Madison, WI 53792
3 shared publications
Latest Publications
- 27 February 2026
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 118 (3)
Cytokines and growth factors produced and released by human eosinophils: lessons from cocultures and omics studies
Besides their largely specific and abundant toxic granule proteins, their Charcot-Leyden crystals, DNA traps, and the release of leukotrienes, human eosinophils are often seen as affecting the immune response and tissue remodeling due to the release of numerous types of cytokines and growth factors. However, the extent of release and the functionality of such mediators, particularly from human eosinophils, remains uncertain. We review the literature focused on cocultures of human eosinophils with other cell types to identify possible cytokines and growth factors secreted by eosinophils and their function(s) on epithelial cells, fibroblasts, lymphocytes, and endothelial cells. Models of coculture include direct cell-to-cell contact, separation with filters, and the use of eosinophil-conditioned media. These models identified cytokines and growth factors as potential eosinophilic factors affecting the behavior of other cell types. In multiple published transcriptome data sets, the expression of these factors in eosinophils was confirmed using human blood and tissue eosinophils, which also allowed us to identify additional potentially important eosinophilic products. The findings in this review support the idea that human eosinophils remain effector cells via their release of toxic proteins (ie EPX/eosinophil peroxidase, RNASE3/eosinophil cationic protein, PRG2/eosinophil major basic protein), Charcot-Leyden crystals of galectin-10, DNA, and leukotrienes, and they produce and release a set of cytokines and growth factors to affect their surroundings.
- 27 February 2026
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 118 (3)
Cytokines and growth factors produced and released by human eosinophils: lessons from cocultures and omics studies
Besides their largely specific and abundant toxic granule proteins, their Charcot-Leyden crystals, DNA traps, and the release of leukotrienes, human eosinophils are often seen as affecting the immune response and tissue remodeling due to the release of numerous types of cytokines and growth factors. However, the extent of release and the functionality of such mediators, particularly from human eosinophils, remains uncertain. We review the literature focused on cocultures of human eosinophils with other cell types to identify possible cytokines and growth factors secreted by eosinophils and their function(s) on epithelial cells, fibroblasts, lymphocytes, and endothelial cells. Models of coculture include direct cell-to-cell contact, separation with filters, and the use of eosinophil-conditioned media. These models identified cytokines and growth factors as potential eosinophilic factors affecting the behavior of other cell types. In multiple published transcriptome data sets, the expression of these factors in eosinophils was confirmed using human blood and tissue eosinophils, which also allowed us to identify additional potentially important eosinophilic products. The findings in this review support the idea that human eosinophils remain effector cells via their release of toxic proteins (ie EPX/eosinophil peroxidase, RNASE3/eosinophil cationic protein, PRG2/eosinophil major basic protein), Charcot-Leyden crystals of galectin-10, DNA, and leukotrienes, and they produce and release a set of cytokines and growth factors to affect their surroundings.
- 8 January 2026
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 118 (2)
Association between absolute blood eosinophil count and carotid plaque and coronary artery calcification in the Multi-Ethnic Study of Atherosclerosis (MESA)
Prior studies have demonstrated associations between eosinophil activation products and incident stroke. We investigated whether circulating eosinophil concentration is associated with imaging markers of atherosclerotic cardiovascular disease (ASCVD), analyzing 2 arterial beds (carotid artery plaque [CAP] and coronary artery calcium [CAC]) in the Multi-Ethnic Study of Atherosclerosis (MESA). The MESA enrolled individuals aged 45 to 84, without ASCVD at baseline. ASCVD risk factors, blood eosinophils, CAP presence/score (0 to 12), and CAC presence/Agatston score were measured at MESA Exam No. 5. Using logistic and linear regression analyses, the relationships between blood eosinophils, CAP or CAC presence, or scores (log[score + 1]), adjusted for confounders, were evaluated. The 2,166 participants were a mean (standard deviation [SD]) 69.6 (9.3) years old, 53% female, 29% Hispanic, 28% Black, 1% Chinese American. The eosinophil count was median (interquartile range) 0.10 (0.10, 0.20)×103/μl, CAP score 2 (0, 4), and CAC score 45 (0, 292) Agatston units. In risk-factor adjusted models, increased blood eosinophil count (per 1 SD [0.15 × 103/μl]) was associated with log scores of CAP (β: 0.05 [95% confidence interval 0.02 to 0.08, P = 0.001) or CAC (β: 0.11, [0.01 to 0.21], P = 0.03). Similar associations were observed for eosinophils and CAP (odds ratio [OR]: 1.12, [1.01 to 1.25], P = 0.03) and CAC (OR: 1.15, [1.02 to 1.30], P = 0.02) presence. In conclusion, in a large, multiethnic US cohort, blood eosinophils were independently linked to imaging atherosclerosis measures in 2 arterial distributions. These data suggest potential roles of eosinophilic inflammation in atherosclerosis.
- 8 January 2026
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 118 (2)
Association between absolute blood eosinophil count and carotid plaque and coronary artery calcification in the Multi-Ethnic Study of Atherosclerosis (MESA)
Prior studies have demonstrated associations between eosinophil activation products and incident stroke. We investigated whether circulating eosinophil concentration is associated with imaging markers of atherosclerotic cardiovascular disease (ASCVD), analyzing 2 arterial beds (carotid artery plaque [CAP] and coronary artery calcium [CAC]) in the Multi-Ethnic Study of Atherosclerosis (MESA). The MESA enrolled individuals aged 45 to 84, without ASCVD at baseline. ASCVD risk factors, blood eosinophils, CAP presence/score (0 to 12), and CAC presence/Agatston score were measured at MESA Exam No. 5. Using logistic and linear regression analyses, the relationships between blood eosinophils, CAP or CAC presence, or scores (log[score + 1]), adjusted for confounders, were evaluated. The 2,166 participants were a mean (standard deviation [SD]) 69.6 (9.3) years old, 53% female, 29% Hispanic, 28% Black, 1% Chinese American. The eosinophil count was median (interquartile range) 0.10 (0.10, 0.20)×103/μl, CAP score 2 (0, 4), and CAC score 45 (0, 292) Agatston units. In risk-factor adjusted models, increased blood eosinophil count (per 1 SD [0.15 × 103/μl]) was associated with log scores of CAP (β: 0.05 [95% confidence interval 0.02 to 0.08, P = 0.001) or CAC (β: 0.11, [0.01 to 0.21], P = 0.03). Similar associations were observed for eosinophils and CAP (odds ratio [OR]: 1.12, [1.01 to 1.25], P = 0.03) and CAC (OR: 1.15, [1.02 to 1.30], P = 0.02) presence. In conclusion, in a large, multiethnic US cohort, blood eosinophils were independently linked to imaging atherosclerosis measures in 2 arterial distributions. These data suggest potential roles of eosinophilic inflammation in atherosclerosis.
- 7 January 2026
- Published by SAGE Publications in Vascular Medicine
- Vol. 31 (1) , 28-34
Carotid artery ultrasound grayscale median and incident dementia: The Multi-Ethnic Study of Atherosclerosis (MESA)
Introduction: Vascular contributions to cognitive impairment and dementia are potentially modifiable. Early detection of reversible arterial injury may improve risk stratification and provide treatment monitoring. We hypothesized that carotid ultrasound grayscale median (GSM), a novel imaging biomarker of early arterial injury, would predict incident all-cause dementia in the Multi-Ethnic Study of Atherosclerosis (MESA). Methods: The MESA enrolled adults free of atherosclerotic cardiovascular disease. Common carotid GSM was measured at baseline. Incident all-cause dementia events were identified by hospital and death records. Cox proportional hazards models with natural cubic splines investigated the association of baseline GSM and all-cause dementia. Results: The 1788 participants were a mean (SD) 63.1 (10.3) years old and 53% were women. Over a median 13.7 years, 157 all-cause dementia events occurred. In fully adjusted models, with additional adjustment for carotid intima–media thickness, lower (worse) GSM independently predicted incident all-cause dementia (hazard ratio, 1st to 3rd tertile, 1.45 [95% CI, 1.11–1.90], p = 0.021). Conclusions: Lower GSM independently predicts all-cause dementia, beyond traditional arterial injury measures, suggesting it may serve as an early marker of dementia risk.
- 7 January 2026
- Published by SAGE Publications in Vascular Medicine
- Vol. 31 (1) , 28-34
Carotid artery ultrasound grayscale median and incident dementia: The Multi-Ethnic Study of Atherosclerosis (MESA)
Introduction: Vascular contributions to cognitive impairment and dementia are potentially modifiable. Early detection of reversible arterial injury may improve risk stratification and provide treatment monitoring. We hypothesized that carotid ultrasound grayscale median (GSM), a novel imaging biomarker of early arterial injury, would predict incident all-cause dementia in the Multi-Ethnic Study of Atherosclerosis (MESA). Methods: The MESA enrolled adults free of atherosclerotic cardiovascular disease. Common carotid GSM was measured at baseline. Incident all-cause dementia events were identified by hospital and death records. Cox proportional hazards models with natural cubic splines investigated the association of baseline GSM and all-cause dementia. Results: The 1788 participants were a mean (SD) 63.1 (10.3) years old and 53% were women. Over a median 13.7 years, 157 all-cause dementia events occurred. In fully adjusted models, with additional adjustment for carotid intima–media thickness, lower (worse) GSM independently predicted incident all-cause dementia (hazard ratio, 1st to 3rd tertile, 1.45 [95% CI, 1.11–1.90], p = 0.021). Conclusions: Lower GSM independently predicts all-cause dementia, beyond traditional arterial injury measures, suggesting it may serve as an early marker of dementia risk.
- 1 August 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 211 (8) , 1515-1518
Proteomic Analysis of Asthma Airway Inflammation after Allergen Challenge: A Heterogeneous Response
- 1 August 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 211 (8) , 1515-1518
Proteomic Analysis of Asthma Airway Inflammation after Allergen Challenge: A Heterogeneous Response
- 7 July 2025
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 13 (7) , 1679-1680
Asthma, β-Agonists, and the Heart: A Tricky Trio
- 7 July 2025
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 13 (7) , 1679-1680
Asthma, β-Agonists, and the Heart: A Tricky Trio
- 25 April 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 63 (4) , 2400469
Asthma and cardiovascular disease: embracing disease heterogeneity is required
Shareable abstract Accounting for the heterogeneity of the asthma syndrome is crucial when investigating the systemic manifestations of asthmahttps://bit.ly/3Tk5UwJ
- 25 April 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 63 (4) , 2400469
Asthma and cardiovascular disease: embracing disease heterogeneity is required
Shareable abstract Accounting for the heterogeneity of the asthma syndrome is crucial when investigating the systemic manifestations of asthmahttps://bit.ly/3Tk5UwJ
- Top Cited Papers
- 12 February 2024
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 12 (4) , 849-862
Systemic Inflammation in Asthma: What Are the Risks and Impacts Outside the Airway?
- 12 February 2024
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 12 (4) , 849-862
Top Cited PapersSystemic Inflammation in Asthma: What Are the Risks and Impacts Outside the Airway?
- 19 July 2023
- Published by Springer Nature
- Vol. 1426, 77-100
Asthma as a Systemic Disease: Cardiovascular Effects Associated with Asthma
Asthma and cardiovascular disease (CVD) pose significant public health burdens. Airway inflammation is central to asthma pathophysiology and systemic inflammation, which occurs in asthma, is central to CVD pathophysiology. Numerous robust epidemiological studies have demonstrated deleterious systemic cardiovascular effects associated with the asthma syndrome. The cardiovascular effects associated with asthma include arterial injury, atherosclerotic CVD events, atrial fibrillation, and hypertension. Asthma is a heterogeneous disease, however, and the risk of CVD is not homogeneous across the various clinical phenotypes and molecular endotypes, highlighting prior inconsistent associations of asthma and its subtypes with various forms of CVD. The mechanistic underpinnings of the increased CVD risk in asthma remain multifactorial and undefined. Collectively, this supports the need for a precision approach in the identification of individuals with asthma who remain at elevated risk of development of cardiovascular diseases to guide both diagnostic and preventive interventions to decrease CVD risk among individuals living with asthma. Keywords Atrial fibrillation Atherosclerotic Cardiovascular Disease Body mass index Inflammation Interleukin-6 Heterogeneity
- 19 July 2023
- Published by Springer Nature
- Vol. 1426, 77-100
Asthma as a Systemic Disease: Cardiovascular Effects Associated with Asthma
Asthma and cardiovascular disease (CVD) pose significant public health burdens. Airway inflammation is central to asthma pathophysiology and systemic inflammation, which occurs in asthma, is central to CVD pathophysiology. Numerous robust epidemiological studies have demonstrated deleterious systemic cardiovascular effects associated with the asthma syndrome. The cardiovascular effects associated with asthma include arterial injury, atherosclerotic CVD events, atrial fibrillation, and hypertension. Asthma is a heterogeneous disease, however, and the risk of CVD is not homogeneous across the various clinical phenotypes and molecular endotypes, highlighting prior inconsistent associations of asthma and its subtypes with various forms of CVD. The mechanistic underpinnings of the increased CVD risk in asthma remain multifactorial and undefined. Collectively, this supports the need for a precision approach in the identification of individuals with asthma who remain at elevated risk of development of cardiovascular diseases to guide both diagnostic and preventive interventions to decrease CVD risk among individuals living with asthma. Keywords Atrial fibrillation Atherosclerotic Cardiovascular Disease Body mass index Inflammation Interleukin-6 Heterogeneity
- Open Access
- 18 July 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (14) , e030139
Effects of an In Vivo Vaping Challenge on In Vitro Interleukin‐6 Biosynthesis Pathways in Arterial Endothelial Cells Derived From Human Embryonic Stem Cells
- 18 July 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (14) , e030139
Open AccessEffects of an In Vivo Vaping Challenge on In Vitro Interleukin‐6 Biosynthesis Pathways in Arterial Endothelial Cells Derived From Human Embryonic Stem Cells